Structure <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Inc. Unveils Promising Preclinical Data for Oral Small Molecule Amylin Agonist ACCG-2671 at ADA Scientific Sessions
Structure Therapeutics Inc. $(GPCR)$, a clinical-stage global biopharmaceutical company, announced two upcoming late-breaking poster presentations at the American Diabetes Association 85th Scientific Sessions, taking place from June 20-23, 2025, in Chicago, IL. The presentations will include new preclinical data on ACCG-2671, an oral small molecule amylin agonist, which is expected to enter clinical development by the end of 2025. The preclinical studies highlighted significant weight-loss effects of ACCG-2671 alone and in combination with a GLP-1 receptor agonist in diet-induced obese rats. Additionally, data on a GLP-1 receptor agonist, GSBR-5595, will be presented, demonstrating neuroprotective effects in a Parkinson's disease mouse model. These findings will be shared on June 22, 2025, during the Late Breaking Poster Session at the event.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Structure Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9472134-en) on June 20, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。